Neurologist Dr. Stewart Tepper explains how the new, "designer" CGRP blocking migraine treatments work, how they are delivered and what to expect for efficacy. These medications come in two different types - gepants and monoclonal antibodies. Dr. Tepper's presentation was recorded in June 2018, after the first of these medications became available to patients in the U.S.
If you support improved access to the best and safest treatments, let your voice be heard. Sign your name to a petition urging healthcare payors to provide better access to migraine treatments. Help us reach 50,000 signatures by December 31, 2020. Sign at www.change.org/MigrainePetition
This podcast is sponsored in part by Alder BioPharmaceuticals and Teva Pharmaceutical Industries.
*The contents of this podcast/video are intended for general informational purposes only and do not constitute medical or legal advice; the content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. The Association of Migraine Disorders does not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.
27 июл 2024
